Illumina

Broad Institute joins Illumina Genome Network

Thursday, February 16, 2012 06:22 AM

The Broad Institute has joined the Illumina Genome Network (IGN) to offer its proprietary sample preparation processes for whole human genome sequencing.

More... »

Illumina’s board unanimously rejects Roche’s offer

Wednesday, February 8, 2012 12:52 PM

Illumina’s board of directors has thoroughly reviewed Roche’s unsolicited tender offer with the assistance of its financial and legal advisors and, according to the company, has unanimously determined that the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina’s stockholders.

More... »


Illumina adopts stockholder Rights Agreement in response to Roche acquisition plan

Thursday, January 26, 2012 01:22 PM

San Diego-based Illumina said its board of directors has adopted a Rights Agreement, pursuant to which one preferred stock purchase right will be distributed as a dividend on each share of Illumina common stock held of record as of the close of business Feb. 6, 2012 (the “Rights”).

More... »

Roche offers to acquire Illumina to strengthen its diagnostics

Wednesday, January 25, 2012 03:11 PM

Roche is proposing to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.

More... »

GenoLogics secures $8 million in strategic financing

Friday, October 21, 2011 02:14 PM

GenoLogics has raised $8 million in strategic financing led by new investor Illumina. The financing will be used to accelerate product development for future clinical applications and new desktop sequencing systems, and to expand sales and marketing functions.

More... »


CWWeekly

February 21

Survey: Sponsors, CROs making changes to their business models to demonstrate value to payers

Cegedim ranks top pharma companies on their use of, and success with, social media

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

February

Anticipating the rise of virtual drug development
With the rising cost of drug development and a continued shortage of new products entering the marketplace, the virtual pharma model is expected to become more prevalent going forward, particularly as pharma companies have...

Closing investigative site operations a complex process
In light of the shrinking investigative site landscape, CenterWatch has conducted in-depth case studies of sites closing their operations. Site personnel offer insights into...

Eye On Shire
Shire is a rapidly growing, global specialty biopharmaceutical company, directly marketing its products in over 50 countries...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.